promitil + folfox

**Promitil + FOLFOX** is an investigational combination chemotherapy regimen composed of Promitil (a pegylated liposomal prodrug of mitomycin C) and the standard FOLFOX regimen (folinic acid, fluorouracil, and oxaliplatin) for oncology indications, primarily colorectal cancer. - **Promitil**: A PEG-liposomal formulation of a mitomycin C lipidic prodrug (MLP) that offers enhanced tumor accumulation, prodrug activation in the tumor microenvironment, improved pharmacokinetics, and lower systemic toxicity compared to free mitomycin C. Promitil acts as a DNA cross-linking agent and has demonstrated potent radiosensitizing properties in preclinical and early clinical settings[7]. - **FOLFOX**: A standard chemotherapeutic combination, consisting of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. Fluorouracil inhibits thymidylate synthase and DNA synthesis; leucovorin enhances 5-FU activity; oxaliplatin induces DNA crosslinks and damage, leading to apoptosis of rapidly dividing cancer cells[1][2][3][4]. Combining Promitil with FOLFOX aims to exploit complementary mechanisms of cytotoxicity, potentially increasing anti-tumor efficacy, particularly where radiosensitization is desirable.

Other names

mitomycin C lipidic prodrug + folinic acid, fluorouracil, oxaliplatin